barzolvolimab Updated Nov 7
The Phase 3 CSU binary is behind the stock (positive Sept 2026). The next major catalyst is the BLA submission planned for 2027, which would trigger a ~12-month FDA review cycle. Watch for the BLA filing announcement and any Phase 2 atopic dermatitis data readout, which could provide additional pipeline optionality. The stock trades at ~$30 with a mean analyst target of $63, reflecting the wide gap between current price and potential approval value.
- Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials met primary and all key secondary endpoints at 12 weeks with both dosing regimens (150mg Q4W and 300mg Q8W), described by management as 'best-in-disease' results.
- Barzolvolimab's novel mechanism (KIT receptor antagonist depleting mast cells) works independently of IgE levels, potentially addressing patients who fail or are not eligible for Xolair.
- Long-term data showed durable off-treatment responses: up to 64% of patients maintained angioedema improvement 7 months after stopping treatment (Week 76).
- Phase 2 prurigo nodularis trial failed to meet its primary endpoint in July 2026, and the program was discontinued, highlighting clinical risk in indication expansion.
- Phase 2 eosinophilic esophagitis program was dropped in August 2025 despite meeting its primary endpoint, suggesting the risk/benefit profile may limit the addressable market.
- The stock fell over 20% on Phase 3 CSU topline day despite positive results, indicating the market may have priced in efficacy or had safety concerns (neutropenia, mast cell depletion).